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Summary of findings {#CD007745-sec1-0001}
===================

Summary of findings for the main comparisonSummary of findings table 1**Ivermectin versus albendazole for treating strongyloides infectionPatient or population:** patients with treating strongyloides infection **Settings:** worldwide **Intervention:** ivermectin versus albendazole**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskAlbendazoleIvermectinCure overall** negative parasitological test Follow‐up: mean 5 weeks**48 per 10084 per 100** (72 to 98)**RR 1.79** (1.55 to 2.08)478 (4 trials)⊕⊕⊕⊝ **moderate**^1^**Adverse events** report of adverse events Follow‐up: mean 5 weeks**26 per 10021 per 100** (15 to 29)**RR 0.80** (0.59 to 1.09)518 (4 trials)⊕⊕⊝⊝ **low**^1,2^\*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Summary of findings 2Summary of findings table 2**Ivermectin versus thiabendazole for treating strongyloides infectionPatient or population:** patients with treating strongyloides infection **Settings:** worldwide **Intervention:** ivermectin versus thiabendazole**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskThiabendazoleIvermectinCure overall** negative parasitological test Follow‐up: mean 11 weeks**69 per 10074 per 100** (66 to 82)**RR 1.07** (0.96 to 1.2)467 (3 trials)⊕⊕⊝⊝ **low**^1^**Adverse events** report of adverse events Follow‐up: mean 11 weeks**73 per 10023 per 100** (15 to 36)**RR 0.31** (0.2 to 0.5)507 (3 trials)⊕⊕⊕⊝ **moderate**^1^\*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^3]

Background {#CD007745-sec1-0002}
==========

Description of the condition {#CD007745-sec2-0001}
----------------------------

### Healthcare problem {#CD007745-sec3-0001}

Strongyloidiasis is an infection caused by the intestinal parasitic worm *Strongyloides stercoralis.* This parasite is tropical and subtropical regions ([@CD007745-bbs2-0081]). Most infected people are asymptomatic, allowing the infection to remain undiagnosed and untreated for years ([@CD007745-bbs2-0048]). However, the infection can cause a serious and sometimes fatal illness in immunosuppressed people ([@CD007745-bbs2-0067]; [@CD007745-bbs2-0081]).

### Geographic distribution {#CD007745-sec3-0002}

*S. stercoralis* is a common intestinal nematode that is more prevalent over 70 subtropical and tropical countries distributed across sub‐Saharan Africa, South‐East Asia, and Central and South America ([@CD007745-bbs2-0081]). The global prevalence was estimated at 39 million cases in 1947 and 100 million cases in 1996 ([@CD007745-bbs2-0047]). The highest prevalence in the world is in rural and remote aboriginal communities, and is a public health problem due to delayed presentation and reduced access to clinical and tertiary care. Strongyloidiasis can be found in non‐endemic areas owing to increases in travel and migration from endemic to non‐endemic countries ([@CD007745-bbs2-0077]).

### Route of infection {#CD007745-sec3-0003}

The parasite has a complex life cycle including a direct, an autoinfective and a non‐parasitic free‐living cycle. Infected people pass first stage larvae in the faeces; these develop on the soil to infective larvae which penetrate the skin of the next host. After a blood‐lung migration, females larvae moult and develop into adult female worms embedded in the submucosa of the duodenum and parthenogenetically produce dozens of embryonated eggs a day. Eggs hatch and produce first stage larvae in the intestinal lumen. Most of these pass out in the faeces and either develop into infective third‐stage larvae or into free‐living adult males and females. Alternatively, larvae may develop to the third stage within the intestinal lumen and penetrate the intestinal mucosa or perianal skin, restarting a new infection cycle without ever leaving their host. The occurrence of the autoinfective larvae is the main reason strongyloidiasis is such a serious disease ([@CD007745-bbs2-0092]; [@CD007745-bbs2-0081]).

### Population at risk {#CD007745-sec3-0004}

The following populations are considered to be at risk of strongyloidiasis ([@CD007745-bbs2-0098]; [@CD007745-bbs2-0046]; [@CD007745-bbs2-0051]):

People living in endemic regions.People with chronic malnutrition.Alcoholics.Travellers.Immigrants.People with malignancies, organ transplantation.People affected by diabetes mellitus, chronic obstructive pulmonary disease (COPD), chronic renal failure.Breast milk from an infected mother.Occupation involving soil.

People who use corticosteroids or other immunosuppressant drugs, have immune deficiency disorders (HTLV‐I or HIV) or who are malnourished are at increased risk of hyperinfection syndrome ([@CD007745-bbs2-0079]; [@CD007745-bbs2-0057]; [@CD007745-bbs2-0091]). Interestingly, although strongyloidiasis is common among acquired immunodeficiency syndrome (AIDS) patients in endemic areas, hyperinfection syndrome is rarely noted ([@CD007745-bbs2-0077]).

### Clinical effects {#CD007745-sec3-0005}

Three clinical presentations of strongyloidiasis are acute infection, chronic intestinal infection and hyperinfection with dissemination.

Acute infection is rarely reported. It may cause local inflammation at the area of larval penetration, appearing as pruritic skin reaction (acute urticaria and itching) of the buttocks, groin and trunk. Pulmonary migration causes respiratory symptoms as the worms travel through the lungs, specifically cough, shortness of breath, and transient wheezing. Diffuse nodular interstitial infiltrates may be seen on chest radiograph or computed tomography (Loeffler´s syndrome). Gastrointestinal symptoms (diarrhoea, constipation, anorexia, and abdominal pain) begin about two weeks after infection and are common in patients with severe strongyloidiasis ([@CD007745-bbs2-0061]). Symptomatic or occult gastrointestinal bleeding is a frequent sign at presentation ([@CD007745-bbs2-0060]). Skin reaction and persistent diarrhoea has been described in international travellers ([@CD007745-bbs2-0080]; [@CD007745-bbs2-0045]).In chronic infection, the worms maintain a low level of reproduction. Most often it is asymptomatic, but gastrointestinal symptoms such as vomiting, diarrhoea, constipation and borborygmus have been reported. Chronic infection is commonly seen in endemic regions and occasionally seen in international travellers and refugees ([@CD007745-bbs2-0067]).Hyperinfection/disseminated syndrome describes an accelerated autoinfection ([@CD007745-bbs2-0075]), and the diagnosis implies the presence of signs and symptoms attributable to increased larval migration to organs beyond the range of the pulmonary autoinfective cycle (dissemination). The invasion of helminths into the mucosa is often associated with Gram‐negative bacterial infections. Mortality, even with treatment, is estimated at 83% to 87% ([@CD007745-bbs2-0071]; [@CD007745-bbs2-0073]). Diseminated infection is seen in patients with steroid therapy ([@CD007745-bbs2-0060]), in HTLV‐1 carriers ([@CD007745-bbs2-0065]), alcoholics ([@CD007745-bbs2-0102]), diabetics ([@CD007745-bbs2-0056]), people with hematologic malignancies and organ transplant recipients ([@CD007745-bbs2-0085]).

### Diagnosis {#CD007745-sec3-0006}

Conventional diagnostic methods, such as the direct smear, formalin ether concentration and filter paper culture methods, cannot produce sufficient sensitivity. Several specimens should be collected on different days to improve detection rate. However, the sensitivity of microscopic‐based techniques might not be good enough, especially in chronic infections where larval output is very low ([@CD007745-bbs2-0087]). However the most sensitive techniques, the Baermann and agar plate methods, are too labour‐intensive to be used in an extensive population ([@CD007745-bbs2-0103]; [@CD007745-bbs2-0101]). Enzyme‐Linked Immunosorbent Assay (ELISA), Immunofluorescence Antibody Test or Indirect Immune Fluorescent Antibody Technique (IFAT), and Western blot have good negative predictive value but cross‐reactivity is observed with filaria ([@CD007745-bbs2-0097]; [@CD007745-bbs2-0073]; [@CD007745-bbs2-0049]). Strongyloides DNA detection in human stool samples by real‐time polymerase chain reaction (PCR) is highly specific with improved sensitivity compared to microscopy ([@CD007745-bbs2-0094]). Luciferase immunoprecipitation system (LIPS) assays are newer immunologic techniques with high sensitivity ([@CD007745-bbs2-0086]).

Description of the intervention {#CD007745-sec2-0002}
-------------------------------

The benzimidazoles (albendazole and thiabendazole) and ivermectin are the drugs most commonly used to treat strongyloidiasis. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend ivermectin as the drug of choice. Thiabendazole or albendazole are considered as alternative therapies ([@CD007745-bbs2-0054]; [@CD007745-bbs2-0095]). A combination therapy with albendazole and ivermectin is recommended in some endemic areas with presence of soil‐transmitted helminthiasis, onchocerciasis and lymphatic filariasis ([@CD007745-bbs2-0099]).

### Benzimidazoles {#CD007745-sec3-0007}

The benzimidazole drugs available for the treatment of strongyloidiasis in humans include thiabendazole and albendazole. Mebendazole is not used for strongyloidiasis for lack of activity. For each of these drugs, the pregnancy risk factor is C, that is, human trials are lacking and animal trials are either positive for foetal risk or lacking as well; however, potential benefits may justify the potential risk ([@CD007745-bbs2-0055]).

Thiabendazole (International Nonproprietary Name: tiabendazole) was the first benzimidazole developed and licensed for human use in 1962 ([@CD007745-bbs2-0066]). Thiabendazole was approved in the USA in 1967 but has subsequently been withdrawn because better tolerated antihelmintic agents are available, such as ivermectin or albendazole. However, thiabendazole is still available in many countries and it is used in veterinary medicine in the USA. Although thiabendazole is active against a variety of intestinal parasites it produces frequent adverse events (nausea, malaise or dizziness ([@CD007745-bbs2-0014]; [@CD007745-bbs2-0004]). Recommended schedule of thiabendazole for parasitic infection is: 50 mg/kg/day divided every 12 hours (maximum 3 g/day) for two days. Many other schedules are used (longer time of treatment or other route of administration than oral). Rectal administration has been reported as successful for treating a patient with hyperinfection and bowel obstruction ([@CD007745-bbs2-0050]).

Albendazole has been used widely since 1982 to treat intestinal parasites. The recommended schedule is an oral dose of 400 mg every 12 hours for seven days. The adverse events have been reported as minor ([@CD007745-bbs2-0078]); severe adverse events are uncommon, although caution is indicated ([@CD007745-bbs2-0070]).

### Ivermectin {#CD007745-sec3-0008}

Ivermectin is an extremely potent, broad‐spectrum, anthelmintic drug that was first introduced for animal use around 1981 and approved for human use in 1988 ([@CD007745-bbs2-0053]). It is a semi‐synthetic macrocyclic lactone (molecular name) derived from avermectin (lactones) of the soil mould, *Streptomyces avermitilis*, causing paralysis in many intestinal parasites through its effect on ion‐channels in cell membranes ([@CD007745-bbs2-0053]). The recommended schedule is 200 µg/kg/day for two days. Many other schedules are used (single dose or a second dose one week later than first one). Ivermectin has been given per rectum as an enema with some success ([@CD007745-bbs2-0093]). Subcutaneous doses of 200 µg/kg every 48 hours has been used with success ([@CD007745-bbs2-0072]; [@CD007745-bbs2-0084]; [@CD007745-bbs2-0089]). Many adverse reactions have been reported, but they usually do not require discontinuation of the drug ([@CD007745-bbs2-0082]). The pregnancy risk factor is C, that is, human trials are lacking and animal trials are either positive for fetal risk or lacking as well ([@CD007745-bbs2-0074]); however, potential benefits may justify the potential risk ([@CD007745-bbs2-0074]).

Ivermectin is being increasingly used worldwide to combat human tropical diseases, such as onchocerciasis (18 million people infected), strongyloidiasis (100 million people infected), scabies (300 million cases annually), pediculosis, gnathostomiasis and myiasis ([@CD007745-bbs2-0059]). Safety trials have shown no serious adverse events in patients treated with ivermectin ([@CD007745-bbs2-0058]). Ivermectin, as well as albendazole and diethylcarbamazine, is also massively used to eliminate lymphatic filariasis through the Global Programme to Eliminate Lymphatic Filariasis ([@CD007745-bbs2-0083]).

How the intervention might work {#CD007745-sec2-0003}
-------------------------------

By binding to free β‐tubulin, benzimidazoles inhibit the polymerization of tubulin and the uptake of glucose causing disruption of microtubule formation in the parasite ([@CD007745-bbs2-0068]).

Ivermectin has potent activity at Gaba‐amino‐butyric‐acid (GABA)‐gated Cl and K channels and glutamate‐gated Cl and K channels, interfering with neural transmission causing paralysis in invertebrates ([@CD007745-bbs2-0053]; [@CD007745-bbs2-0062]).

Why it is important to do this review {#CD007745-sec2-0004}
-------------------------------------

The control of strongyloidiasis as a public health problem is not a priority for governments ([@CD007745-bbs2-0081]). Moreover, the treatment is not universally available, although drugs are listed in the essential medicines of the WHO ([@CD007745-bbs2-0100]). The introduction of treatment with ivermectin as annually mass treatment in endemic communities of onchocerciasis has shown a reduction in transmission in endemic communities and reduce the expected number of new infections ([@CD007745-bbs2-0096]). Ivermectin is currently employed by the African Programme for Onchocerciasis Control (APOC) and the Onchocerciasis Elimination Programme for the Americas (OEPA) for mass treatment in endemic communities. Trials of long‐term treatment with ivermectin to control lymphatic filariasis have shown that use of the drug is additionally associated with significant reduction in the prevalence of infection with any soil‐transmitted helminth parasites, most or all of which are deemed to be major causes of the morbidity arising from poor childhood nutrition and growth ([@CD007745-bbs2-0076]). Mass treatment with ivermectin have been effective to eliminate both infections and seems to be the ideal drug for such interventions ([@CD007745-bbs2-0063]).

This Cochrane Review aimed to summarise systematically all the evidence from randomized controlled trials (RCTs) relating to the effectiveness of ivermectin in chronic strongyloidiasis in order to provide current best evidence on which to base decisions for practice and further research.

Objectives {#CD007745-sec1-0003}
==========

To assess the effects of ivermectin versus benzimidazoles (albendazole and thiabendazole) for treating chronic strongyloides infection.

Methods {#CD007745-sec1-0004}
=======

Criteria for considering studies for this review {#CD007745-sec2-0005}
------------------------------------------------

### Types of studies {#CD007745-sec3-0009}

Randomized controlled trials (RCTs).

### Types of participants {#CD007745-sec3-0010}

Participants were people (all ages) who were immunocompetent or immunocompromised, and with chronic infection by *S. stercoralis* confirmed by parasitological examination (at least one positive specimen) or serology tests (IFAT).

We defined immunocompromised people as those affected by haematological malignancies, bone marrow and kidney transplants, hypogammaglobulinaemia (low gamma globulin in blood), malnutrition, HTLV‐1/HIV infection or co‐infection, or who are using corticosteroids.

### Types of interventions {#CD007745-sec3-0011}

Ivermectin versus albendazole or thiabendazole.

### Types of outcome measures {#CD007745-sec3-0012}

#### Primary outcomes {#CD007745-sec4-0001}

Elimination of infection or parasitological cure: defined as any parasitological exam negative during follow‐up period (more than two stool samples negative).

#### Secondary outcomes {#CD007745-sec4-0002}

Death;Adverse events as reported in trials:Serious adverse events (requires inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; or is life threatening).Adverse events leading to discontinuation of treatment.Other adverse events.

Search methods for identification of studies {#CD007745-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press and in progress).

### Electronic searches {#CD007745-sec3-0013}

We searched the following databases using the search terms detailed in [Appendix 1](#CD007745-sec2-0016){ref-type="app"}: the Cochrane Infectious Diseases Group (CIDG) Specialized Register (24 August 2015); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (January 1966 to August 2015); EMBASE (January 1980 to August 2015); and LILACS (August 2015). We also searched the *meta*Register of Controlled Trials (*m*RCT) using \'strongyloid\*\' as a search term.

### Searching other resources {#CD007745-sec3-0014}

We searched the reference lists of identified trials to find additional trials. We searched the following conference proceedings for relevant abstracts: the Annual Congress of the American Society for Tropical Medicine and Hygiene (2005 to 2015); and the European Congress on Tropical Medicine and International Health (2009 to 2015). To help identify unpublished and ongoing trials, we contacted relevant organizations including tropical medicine and infectious disease institutes in Japan, and Peru, and pharmaceutical companies including Merck & Co., Inc. However, our attempts to contact trial authors were unsuccessful.

Data collection and analysis {#CD007745-sec2-0007}
----------------------------

### Selection of studies {#CD007745-sec3-0015}

Cesar Henriquez‐Camacho (CHC) with assistance from Vittoria Lutje, the CIDG Information Retrieval Specialist, searched the literature and retrieved trials. Juan Echevarria (JE) and Frine Samalvides (FS) retrieved the full reports of potentially relevant trials and then applied the inclusion criteria to the full reports using an eligibility form. If eligibility was unclear, we tried to contact the trial authors for clarification. Eduardo Gotuzzo (EG) resolved any disagreements. We scrutinized the eligible trials to ensure that each trial was included only once. We listed the trials that were not eligible for inclusion and explain the reasons for exclusion.

### Data extraction and management {#CD007745-sec3-0016}

One review author (CHC) extracted the data, and JE and Maria N Plana (MNP) crossed‐check the data with the original paper for accuracy. We used a data extraction form, which was piloted previously. CHC entered the data into [@CD007745-bbs2-0088]. We resolved discrepancies by discussion.

We extracted data for dichotomous variables as the number of events and the number of participants in each group for all outcomes. We calculated the percentage lost to follow‐up in each group. Also, we extracted and recorded data on the following: characteristics of participants, characteristics of interventions, characteristics of outcome measures, date of trial, trial authors, location of trial, sponsor of trial (specified, known or unknown), design (described as randomized or not), participants (strongyloidiasis confirmed), interventions (treatment, days, doses), outcomes (treatment failure, parasite clearance, adverse events) and data known to have been collected by trialists but not included in the report (where possible).

### Assessment of risk of bias in included studies {#CD007745-sec3-0017}

Two review authors (CHC and MNP) independently assessed the risk of bias of each included trial using the criteria outlined in the Cochrane \'Risk of bias\' tool ([@CD007745-bbs2-0064]). A third review author (EG) resolved any disagreements. We considered the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding for participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other sources of bias. We classified each domain as being at \'low\', \'high\' or \'unclear\' risk of bias. We included a \'Risk of bias\' graph ([Figure 1](#CD007745-fig-0001){ref-type="fig"}) and a \'Risk of bias\' summary ([Figure 2](#CD007745-fig-0002){ref-type="fig"}).Figure 1Methodological quality graph: review authors\' judgements about each methodological quality item presented as percentages across all included trials.Figure 2Methodological quality summary: review authors' judgements about each methodological quality item for each included trial.

### Measures of treatment effect {#CD007745-sec3-0018}

We used risk ratios (RR) with 95% confidence intervals (CIs) and fixed‐effect models to analyse the efficacy data.

### Assessment of heterogeneity {#CD007745-sec3-0019}

We assessed statistical heterogeneity by examining the forest plots and using the I² statistic and Chi² test values. We regarded heterogeneity as substantial if the I² statistic was \> 50% or there was a low P value (\< 0.10) in the Chi² test for heterogeneity.

### Assessment of reporting biases {#CD007745-sec3-0020}

We planned to construct funnel plots to look for evidence of publication bias, provided there were a sufficient number of trials included to make this analysis informative.

### Data synthesis {#CD007745-sec3-0021}

We computed pooled estimates of effect separately for each comparison we had data for (ivermectin versus albendazole; and ivermectin versus thiabendazole).

We used [@CD007745-bbs2-0088] for data analysis.

For the analysis of adverse events, we needed to ascertain the number of participants who experienced the adverse events. We used the rate ratio to pool adverse event data if the trials were sufficiently similar in their adverse event definitions. We excluded data from trials that only reported the number of adverse events as it is possible that an individual could have more than one adverse event reported. If these adverse events were reported by randomized groups, we included the data in the analysis.

We used a fixed‐effect model for combining data where it was reasonable to assume that trials were estimating the same treatment effect. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we detected substantial statistical heterogeneity, we used a random‐effects model. If we used random‐effects analysis, we presented the results as the average treatment effect with its 95% CIs, and the estimates of the I² statistic.

### Subgroup analysis and investigation of heterogeneity {#CD007745-sec3-0022}

We attempted to explain any heterogeneity through subgroup analyses. We planned to conduct the following subgroup analyses of primary outcome in both comparisons (ivermectin versus albendazole & ivermectin versus thiabendazole): type of population (endemic and non‐endemic areas) and doses of ivermectin (single versus double doses).

### Sensitivity analysis {#CD007745-sec3-0023}

We planned sensitivity analyses to explore whether trials at high risk of bias overestimated the effect of treatment.

Results {#CD007745-sec1-0005}
=======

Description of studies {#CD007745-sec2-0008}
----------------------

See [Characteristics of included studies](#CD007745-sec2-0019){ref-type="sec"}; [Characteristics of excluded studies](#CD007745-sec2-0020){ref-type="sec"}; [Characteristics of ongoing studies](#CD007745-sec2-0021){ref-type="sec"} sections.

### Results of the search {#CD007745-sec3-0024}

The electronic search generated 50 citations and abstracts, and three conference reports. We screened these articles and only seven trials including 1147 participants met the inclusion criteria ([Figure 3](#CD007745-fig-0003){ref-type="fig"}). None were cluster‐randomized. Communication with Merck & Co., Inc, the manufacturers of Mectizan and with experts in the field did not yield information on any further trials. Only two trial authors provided further information about included trials ([@CD007745-bbs2-0005]; [@CD007745-bbs2-0002]).Figure 3Trial flow diagram.

### Included studies {#CD007745-sec3-0025}

See [Characteristics of included studies](#CD007745-sec2-0019){ref-type="sec"}.

#### Setting and participants {#CD007745-sec4-0003}

Four trials took place in endemic communities in Zanzibar ([@CD007745-bbs2-0005]), Nigeria ([@CD007745-bbs2-0001]) and Thailand ([@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]). Three trials recruited participants from endemic areas living in non‐endemic countries in the USA ([@CD007745-bbs2-0004]), France ([@CD007745-bbs2-0003]), and travellers or immigrants residing in Italy ([@CD007745-bbs2-0002]). Two trials included only adults ([@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]), and five trials included adults and children ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0004]; [@CD007745-bbs2-0005]; [@CD007745-bbs2-0001]; [@CD007745-bbs2-0002]). Only two trials included immunocompromised participants ([@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]), although the number of immunocompromised and immunocompetent participants was unclear. The authors of two trials were contacted and responded ([@CD007745-bbs2-0005]; [@CD007745-bbs2-0002]).

#### Interventions {#CD007745-sec4-0004}

In all included trials ivermectin was compared with a benzimidazole (two trials specified MECTIZAN®, one specified IVOMEC® from Merck Sharp Dome, and one VERMECTIN® from Atlantic Laboratories Co. Ltd.). Three trials compared ivermectin versus thiabendazole (one specified MINTEZOL® from Merck Sharp Dome) ([@CD007745-bbs2-0004]; [@CD007745-bbs2-0001]; [@CD007745-bbs2-0002]) and four trials compared ivermectin versus albendazole (one specified ALBATEL® from TO Chemicals and one specified ZENTEL® from SmithKline Beecham) ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0005]; [@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]). The usual dose of ivermectin was 200 μg/kg body weight; however, [@CD007745-bbs2-0004], and [@CD007745-bbs2-0007] had two treatment groups of one single dose and two doses. The dose of albendazole was 400 mg twice daily for seven days in two trials ([@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]) and 400 mg twice daily for three days in two trials ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0005]).

#### Outcome measures {#CD007745-sec4-0005}

Assessment of outcome measures was by parasitological examination. This included direct stool examination, Kato‐Katz technique, Baermann test, Agar plate culture, formol‐ether concentration and IFAT. The included trials did not define who undertook the outcome assessments. Trials assessed and reported outcome measures differently, depending on the technique used.

Two trials used the Baermann technique as the only diagnostic method ([@CD007745-bbs2-0004]; [@CD007745-bbs2-0001]). The rest of the included trials used two or more diagnostic methods. Four trials used stool examination, according to Baermann, as the assessment method. Only one trial, [@CD007745-bbs2-0002], used a serological test (IFAT) with agar plate.

The number of stool samples varied between two to nine, but the results of each sample were not always reported. There was lack of uniformity in follow‐up (mean of follow‐up: 7.5 weeks (range: two to 24 weeks)).

Only one trial evaluated clinical improvement through medical interview ([@CD007745-bbs2-0004]). There were several adverse events reported, but there were no deaths after administration of drugs or by the disease itself. For more detailed information on individual trials see [Characteristics of included studies](#CD007745-sec2-0019){ref-type="sec"}.

### Excluded studies {#CD007745-sec3-0026}

We excluded 36 trials from the review (see [Characteristics of excluded studies](#CD007745-sec2-0020){ref-type="sec"}).

Risk of bias in included studies {#CD007745-sec2-0009}
--------------------------------

We have listed summary details in the [Characteristics of included studies](#CD007745-sec2-0019){ref-type="sec"} section. [Figure 1](#CD007745-fig-0001){ref-type="fig"} and [Figure 2](#CD007745-fig-0002){ref-type="fig"} summarise the \'Risk of bias\' assessment in the included trials.

### Allocation {#CD007745-sec3-0027}

Two trials were the only trials that reported adequate methods of allocation concealment ([@CD007745-bbs2-0002]; [@CD007745-bbs2-0007]). Five trials reported adequate methods of random sequence generation ([@CD007745-bbs2-0004]; [@CD007745-bbs2-0005]; [@CD007745-bbs2-0001]; [@CD007745-bbs2-0002]; [@CD007745-bbs2-0007]). Only two trials had low risk of bias both for random sequence generation and allocation concealment ([@CD007745-bbs2-0002]; [@CD007745-bbs2-0007]).

### Blinding {#CD007745-sec3-0028}

All the trials were unblinded, but the lack of blinding could not have affected the results because the primary outcome (parasitological cure) was objectively measured.

### Incomplete outcome data {#CD007745-sec3-0029}

One trial was considered at high risk of bias because of the high number of losses to follow‐up ([@CD007745-bbs2-0005]). Four of the seven included trials did not provide enough information to assess attrition bias and were classified as having an unclear risk of bias.

### Selective reporting {#CD007745-sec3-0030}

Only one trial protocol was available and could be assessed for selective reporting bias ([@CD007745-bbs2-0002]). However, all trials have been classified as low risk of reporting bias. The principal outcomes (parasitological cure and adverse events) were communicated in all reports.

### Other potential sources of bias {#CD007745-sec3-0031}

Only one trial stopped recruitment early ([@CD007745-bbs2-0002]). There were not explicitly defined criteria for the early conclusion of the trial (see [Characteristics of included studies](#CD007745-sec2-0019){ref-type="sec"}).

Effects of interventions {#CD007745-sec2-0010}
------------------------

See: [Table 1](#CD007745-tbl-0001){ref-type="table"}; [Table 2](#CD007745-tbl-0002){ref-type="table"}

All seven included trials measured parasitological cure at different follow‐up periods (from two to 24 weeks) ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0004]; [@CD007745-bbs2-0005]; [@CD007745-bbs2-0001]; [@CD007745-bbs2-0006]; [@CD007745-bbs2-0002]; [@CD007745-bbs2-0007]). Four trials compared ivermectin versus albendazole ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0005]; [@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]) and three trials compared ivermectin versus thiabendazole ([@CD007745-bbs2-0004]; [@CD007745-bbs2-0001]; [@CD007745-bbs2-0002]).

### Comparison 1: Ivermectin versus albendazole {#CD007745-sec3-0032}

#### Parasitological cure {#CD007745-sec4-0006}

See [Table 1](#CD007745-tbl-0001){ref-type="table"}.

Parasitological cure was higher with ivermectin (RR 1.79, 95% CI 1.55 to 2.08; 478 participants; four trials; [Analysis 1.1](#CD007745-fig-00101){ref-type="fig"}; [Figure 4](#CD007745-fig-0004){ref-type="fig"}). This effect was consistent despite the geographical origin of the population (RR 1.75, 95% CI 1.50 to 2.04; 425 participants; three trials in endemic areas; and RR 2.21, 95% CI 1.28 to 3.80; 53 participants; one trial in non‐endemic areas; [Analysis 1.2](#CD007745-fig-00102){ref-type="fig"}). The subgroup analysis performed by dosage of ivermectin included four trials assessing single doses (200 μg/kg) ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0005]; [@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]) and one trial assessing double doses (200 μg/kg for two consecutive days; [@CD007745-bbs2-0007]). There were no differences when ivermectin single or double dose was compared to albendazole (P = 0.18), *low quality evidence*;[Analysis 1.3](#CD007745-fig-00103){ref-type="fig"}).Figure 4Forest plot of comparison: 1 Ivermectin versus albendazole, outcome: 1.1 Parasitological cure.

Only two trials included immunocompromised patients, although the number of patients was unclear ([@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]). These trials showed higher cure with ivermectin (RR 1.78, 95% CI 1.06 to 2.98 and RR 1.50, 95% CI 1.14 to 1.98, respectively). These trials did not provide any subgroup analyses for immunocompromised patients.

Sensitivity analysis excluding trials with unclear number of immunocompromised patients ([@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]) had no impact on the estimated efficacy of ivermectin (RR 1.89, 95% CI 1.58 to 2.27; 354 participants; two trials; [Analysis 1.4](#CD007745-fig-00104){ref-type="fig"}).

One trial, [@CD007745-bbs2-0002], excluded participants with immunodeficiencies and the remaining trials reported the exclusion of hematologic abnormalities. However it was unclear whether participants were assessed for immunocompetence.

#### Death {#CD007745-sec4-0007}

There was no mortality reported as related to treatment. [@CD007745-bbs2-0007] reported 15 deaths related to underlying diseases as solid tumours, haematological malignancies, diabetes, lupus, myocardial infarction and sepsis.

#### Adverse events {#CD007745-sec4-0008}

There were no reports of serious adverse events. Ivermectin was at least as well tolerated as albendazole (RR 0.80, 95% CI 0.59 to 1.09; 518 participants, four trials, *very low quality evidence*; [Analysis 1.5](#CD007745-fig-00105){ref-type="fig"}; [Figure 5](#CD007745-fig-0005){ref-type="fig"}). [Table 6](#CD007745-tbl-0006){ref-type="table"} summarises further the information related to adverse events of the primary trials.Figure 5Forest plot of comparison: 1 Ivermectin versus albendazole, outcome: 1.5 Clinical adverse events.Table 1Comparison 1: Ivermectin versus albendazole. Adverse events (clinical and laboratory)**TrialAssessment methodTimingIvermectinAlbendazole**[@CD007745-bbs2-0003]\"Tolerance were evaluated at each visit by a thorough questionnaire and physical examination. Hepatic, renal and haematological functions were investigated before treatment and on day 7\"\"Tolerance of drugs were evaluated on days 7, 30 and 90\"Evaluted for AEs 29 patients:\
fatigue, nausea, tremor: 1 (3%); elevation of transaminases: 1 (3%);\
anaemia and leukopenia: 1 (3%)Evaluted for AEs 24 patients:\
abdominal pain, nausea and dizziness: 2 (8%);\
elevation of transaminases: 1 (4%)[@CD007745-bbs2-0005]Standardized questionnaire\"The assessment for side effects of the drug regimen was performed three days after start of treatment\...and three weeks after the end of treatment\"Evaluated for AEs 163 patients:\
abdominal distension: 7 (4%);chest pain: 7 (4%);loose stools: 16 (10%);headache: 15 (9%);cough: 11 (7%);fever: 10 (6%);dizziness: 5 (3%);nausea: 5 (3%);itching: 3 (2%);watery diarrhoea: 2 (1%)Evaluated for AEs 170 patients:\
abdominal distension: 1 (6%);chest pain: 0 (0%);loose stools: 17 (10%);headache: 18 (11%);cough: 8 (5%);fever: 7 (4%);dizziness: 10 (6%);nausea: 6 (4%);itching: 6 (4%);watery diarrhoea: 3 (2%)[@CD007745-bbs2-0006]Biochemical and haematological tests\"one week after enrolment\"Evaluated for AEs 18 patients:\
acute generalised exanthematous pustulosis (AGEP): 1(6%);elevation of transaminases: 1 (6%)Evaluated for AEs 16 patients:\
elevation of transaminases: 3 (19%)[@CD007745-bbs2-0007]\"Adverse events were defined as symptoms or signs that developed after the trial drug administration and had not been reported prior to the administration of the first dose of the antihelmintic\"Not describedEvaluated for AEs 60 patients:\
elevation of transaminases: 1 (2%)Evaluated for AEs 30 patients:\
severe nausea and vomiting: 1 (3%)[^4]

In ivermectin group, the adverse events most frequently reported were loose stools (10%), cough (7%), headache (9%) and fever (6%) ([@CD007745-bbs2-0005]); fatigue, nausea and tremor (3%) ([@CD007745-bbs2-0003]). In [@CD007745-bbs2-0006], one patient had acute generalized exanthematous pustulosis of moderate severity probably drug‐related.

In albendazole group, the adverse events most frequently reported were headache (11%), loose stools (10%), dizziness (6%) and cough (5%) ([@CD007745-bbs2-0005]); nausea and dizziness (8%) ([@CD007745-bbs2-0003]). None of them caused discontinuation of participants\' normal daily activities. Severe nausea and vomiting were reported in one patient in the albendazole group ([@CD007745-bbs2-0007]).

#### Adverse analytical changes {#CD007745-sec4-0009}

Three trials ([@CD007745-bbs2-0003]; [@CD007745-bbs2-0006]; [@CD007745-bbs2-0007]) reported a modest elevation of transaminases suggesting hepatotoxicity in both the ivermectin and albendazole treatment arms. Other abnormalities included anaemia and leucopenia in ivermectin group ([@CD007745-bbs2-0003]; see [Table 6](#CD007745-tbl-0006){ref-type="table"}). Transaminase levels returned to normality within a month (three to four weeks) and the haematological abnormalities disappeared within two months after treatment discontinuation.

### Comparison 2: Ivermectin versus thiabendazole {#CD007745-sec3-0033}

#### Parasitological cure {#CD007745-sec4-0010}

See [Table 2](#CD007745-tbl-0002){ref-type="table"}.

Parasitological cure was not different between ivermectin and thiabendazole (RR 1.07, 95% CI 0.96 to 1.20; 467 participants, three trials; [Analysis 2.1](#CD007745-fig-00201){ref-type="fig"}; [Figure 6](#CD007745-fig-0006){ref-type="fig"}). The geographical origin did not modified the effect of either treatments (RR 1.07, 95% CI 0.94 to 1.22; 216 participants, one trial in endemic areas; and RR 1.08, 95% CI 0.90 to 1.29; 251 participants, two trials in non‐endemic areas; [Analysis 2.2](#CD007745-fig-00202){ref-type="fig"}). The subgroup analysis performed by dosage of ivermectin included two trials assessing single doses (200 μg/kg) ([@CD007745-bbs2-0001]; [@CD007745-bbs2-0002]) and one trial assessing double doses (200 μg/kg for two consecutive days) ([@CD007745-bbs2-0004]). There were no differences when ivermectin single or double dose was compared to thiabendazole (P = 0.92),*low quality evidence*; [Analysis 2.3](#CD007745-fig-00203){ref-type="fig"}).Figure 6Forest plot of comparison: 2 Ivermectin versus thiabendazole, outcome: 2.1 Parasitological cure.

#### Death {#CD007745-sec4-0011}

There was no mortality reported as related to treatment.

#### Adverse events {#CD007745-sec4-0012}

Severe drug reaction was not reported. The incidence of adverse events was higher in the thiabendazole group than in the ivermectin group (RR 0.31, 95% CI 0.20 to 0.50; 507 participants; three trials; [Analysis 2.4](#CD007745-fig-00204){ref-type="fig"}; [Figure 7](#CD007745-fig-0007){ref-type="fig"}). [Table 7](#CD007745-tbl-0007){ref-type="table"} summarises further the information related to adverse events of the primary trials.Figure 7Forest plot of comparison: 2 Ivermectin versus thiabendazole, outcome: 2.4 Clinical adverse events.Table 2Comparison 2: Ivermectin versus thiabendazole. Adverse events (clinical and laboratory)**TrialAssessment methodTimingIvermectinThiabendazole**[@CD007745-bbs2-0001]\"Voluntary spontaneous complaints by subjects and also by interviews conducted using a standard questionnaire based on the common adverse effects of either drug reported in the literature\"7 days post‐treatmentEvaluated for AEs 122 patients:\
fatigue: 16 (13%);headache: 11 (9%);fever: 8 (7%);constipation: 7 (6%);nausea: 5 (4%);dizziness: 6 (5%);malaise: 0 (0%);anorexia: 0 (0%);abdominal pain: 0 (0%);disorientation: 0 (0%)Evaluated for AEs 109 patients:\
fatigue: 54 (50%);headache: 7 (6%);fever: 0 (0%);constipation: 0 (0%);nausea: 49 (45%);dizziness: 28 (26%);malaise: 21 (19%);anorexia: 39 (36%);abdominal pain: 6 (6%);disorientation: 16 (15%)[@CD007745-bbs2-0002]\"reported by patients\"Days 1 and 2 of treatment and during scheduled and unscheduled visitsEvaluated for AEs 115 patients:\
dizziness: 12 (10%);drowsiness (data not reported)Evaluated for AEs 108 patients:\
dizziness: 57 (53%);nausea and vomiting (data not reported)[@CD007745-bbs2-0004]\"To assess drug safety, we took patient histories, did physical examination and ran complete blood cell counts and serum chemistries (including liver function test)\"Before and on day 7 after treatmentEvaluated for AEs 34 patients:\
itching: 4 (12%);lightheadedness: 3 (9%);fatigue: 2 (6%);nausea: 1 (3%);constipation: 1 (3%);disorientation: 0 (0%);anorexia: 0 (0%);abdominal pain: 0 (0%)Evaluated for AEs 19 patients:\
itching: 0 (0%);lightheadedness: 0 (0%);fatigue: 15 (79%);nausea: 13 (68%);constipation: 0 (0%);disorientation: 17 (89%);anorexia: 11 (58%);abdominal pain: 1(5%);elevation of transaminases: 1 (5%)[^5]

In ivermectin group, adverse events frequently described were fatigue (13%) and headache (9%) ([@CD007745-bbs2-0001]); dizziness and drowsiness (10%) ([@CD007745-bbs2-0002]); and itching (12%) and lightheadedness (9%) ([@CD007745-bbs2-0004]).

In thiabendazole group, adverse events frequently described were fatigue (50%), nausea (45%), anorexia (36%) and dizziness (26%) ([@CD007745-bbs2-0001]); dizziness (53%), nausea and vomiting ([@CD007745-bbs2-0002]); disorientation (89%), fatigue (79%) and nausea (68%) ([@CD007745-bbs2-0004]).

#### Adverse analytical changes {#CD007745-sec4-0013}

In [@CD007745-bbs2-0004], a modest elevation of transaminases was reported to cause hepatotoxicity ([Table 7](#CD007745-tbl-0007){ref-type="table"}).

### Comparison 3: Single dose versus double dose ivermectin {#CD007745-sec3-0034}

Two trials assessed single (200 μg/kg) versus double doses (200 μg/kg for two consecutive days) of ivermectin ([@CD007745-bbs2-0004]; [@CD007745-bbs2-0007]). Taking double doses of ivermectin was not associated with higher cure (RR 1.02, 95% CI 0.94 to 1.11; 94 participants; two trials; [Analysis 3.1](#CD007745-fig-00301){ref-type="fig"}).

Discussion {#CD007745-sec1-0006}
==========

Summary of main results {#CD007745-sec2-0011}
-----------------------

We undertook this Cochrane Review to assess the effectiveness of ivermectin compared with albendazole and thiabendazole in the parasitological cure of chronic strongyloidiasis.

The results suggest that there is evidence of low to moderate quality that ivermectin is superior in terms of efficacy than albendazole but, given the low overall incidence of adverse effects, meta‐analyses may be underpowered to confidently detect differences in the incidence of adverse events between both treatments (see [Table 1](#CD007745-tbl-0001){ref-type="table"}). There is evidence of low to moderate quality that ivermectin appears to be as effective as thiabendazole, and presents less adverse events (see [Table 2](#CD007745-tbl-0002){ref-type="table"}).

Subgroup analyses showed no differences in the efficacy of ivermectin according to type of population (endemic versus non endemic) neither for the comparison with albendazole nor thiabendazole.

We found no difference in the parasitological cure according to dosage (single dose or double doses) of ivermectin, although this result is based on only two trials with few patients.

Dizziness, nausea and disorientation were the most frequent adverse events reported in the included trials. Although albendazole and thiabendazole belong to the same drug family (benzimidazoles), they have different effects and different adverse events. In the current review, adverse events were generally poorly assessed. The most frequent abnormal laboratory test in patients that received benzimidazoles was hepatotoxicity (increase in transaminase levels). However, the clinical significance of this effect was no serious and all patients recover the normal levels in approximately three weeks.

Overall completeness and applicability of evidence {#CD007745-sec2-0012}
--------------------------------------------------

These findings are of importance for clinical perspectives. The results of this Cochrane Review don\'t allow formulation of clear public health conclusions, due to the low quality of evidence on the efficacy of treatment for strongyloides and the scarce data on safety. To date, no public health strategy has been developed to control strongyloidiasis. However since 1989, the WHO Onchocerciasis Control Programme has fought against onchocerciasis by means of mass administration of ivermectin and vector control initiatives. Similarly, since 2000, albendazole either with ivermectin or diethylcarbamazine citrate has been the cornerstone of the WHO Global Programme to Eliminate Lymphatic Filariasis. In those areas where mass treatment with ivermectin has been used to control onchocerciasis or lymphatic filariasis, the prevalence of infection with soil‐transmitted helminth parasites, has been reduced, most or all of which are deemed to be a major cause of the morbidity arising from childhood nutrition and growth. This could have impact on the incidence of strongyloidiasis in endemic areas, but there is no clear data on this.

There is no report on resistance to ivermectin which is a favourable factor to be used in mass community treatment. The WHO recommends double therapy with ivermectin and albendazole in endemic areas with coinfection of soil‐transmitted helminthiasis and lymphatic filariasis; and triple therapy with ivermectin, albendazole and praziquantel in schistosomiasis‐endemic areas. Thiabendazol seems to be as effective as ivermectin but is not produced in a lot of countries. Being albendazole less effective than ivermectin, it is considered a better alternative treatment for strongyloidiasis than thiabendazole.

All trials included patient with chronic strongyloidiasis. We have no evidence about the impact of ivermectin on other clinical stages (acute strongyloidiasis or hyperinfection syndrome). The more effective dose of ivermectin (single or double) is a question that remains unanswered and deserves further rigorous research. Five out of seven trials included only immunocompetent patients and only two trials included an unknown proportion of immunocompromised patients. It is known that immunocompromised people are the most vulnerable population at risk for developing fatal illness. Unfortunately the review provides little information about the treatment effects on this vulnerable population.

This Cochrane Review does not provide information about the ideal doses for different ages. We cannot answer the question as to the benefit of ivermectin in very young or very old people as most of the trials did not include information about effectiveness and age.

The effect of ivermectin in preventing new infections is not assessed. The trials included in this systematic review were not primarily designed to evaluate the effectiveness of ivermectin in preventing new infections of strongyloidiasis and this outcome was not commonly reported.

Quality of the evidence {#CD007745-sec2-0013}
-----------------------

Many trials did not adequately report the trial characteristics that are important to evaluate the quality of the evidence. Most trials did not explain if, or how, the sample size was predetermined and many had small sample sizes. Almost none of the trials used an adequate method of allocation concealment nor blindness. However we have considered that lack of blindness has a low risk of bias because the measurement of the outcome (parasitological cure) was done objectively. Also, there was insufficient information to assess the attrition bias of the trials included; we classified four of the seven included trials as having an unclear risk of bias.

Potential biases in the review process {#CD007745-sec2-0014}
--------------------------------------

Publication bias is a major threat to the validity of systematic reviews. To minimize the risk of publication bias, we conducted a comprehensive search across numerous clinical trial databases. Nonetheless, as for any systematic review, we cannot rule out the influence of publication bias. Unfortunately given the small number of included trials we were impeded to reliably assess the presence of publication bias.

Agreements and disagreements with other studies or reviews {#CD007745-sec2-0015}
----------------------------------------------------------

We have not identified any trials similar to this Cochrane Review. A systematic review was published on 2009 ([@CD007745-bbs2-0090]) about prophylaxis for strongyloidiasis hyperinfection which objective was to determine patterns of prophylaxis in hyperinfection syndrome in immunosuppressed rheumatology patients. Another systematic review was published on 2013 about case reports and short cases of hyperinfection syndrome (HS) and disseminated strongyloidiasis (DS) described 244 cases treated with different drugs, administration route and duration. Similar fatality rate was observed between patients with DS (68.5%) and HS (60%) ([@CD007745-bbs2-0052]).

Authors\' conclusions {#CD007745-sec1-0007}
=====================

More people are cured with ivermectin than with albendazole for chronic strongyloidiasis, and it does not have more adverse effects. Ivermectin results in similar cure rates when compared to thianbendazole, but there are more adverse effects with thiabendazole. The most effective dose of ivermectin (single or double) is a question that remains still unanswered and deserves further research.For patients with some underlying immunosuppressive disorder, or in patients who are very young or very old, current data are insufficient to make a conclusive statement as regards appropriate management.Well‐designed trials may help investigate the effect of different doses (single, double or multiple doses) and regimens of ivermectin to identify appropriate doses for treatment and prophylaxis in different group of patients to facilitate adherence.The single most important problem posed by strongyloidiasis is its potential to produce a hyperinfection syndrome in vulnerable population. Future trials could focus in such population. We are unable to comment on the effects of ivermectin in other syndromes, specially in the high‐risk groups for hyperinfection syndrome.

The editorial base for the CIDG is funded by UKaid from the UK Government for the benefit of developing countries.

We are grateful to Harriet MacLehose, Vittoria Lutje and CIDG editorial staff. Also, we thank Paul Garner, Reive Robb, Anne‐Marie Stephani, Xavier Bonfil and Marta Roque for helping us to complete this Cochrane Review version.

We acknowledge everyone who responded to queries regarding ivermectin trials for strongyloidiasis.

**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^**1strongyloid\*STRONGYLOIDESSTRONGYLOIDESSTRONGYLOIDIASISstrongyloid\*2thiabendazoleSTRONGYLOIDES STERCORALISSTRONGYLOIDES STERCORALISSTRONGYLOIDIASIS‐INFECTIONthiabendazole3albendazolestrongyloid\*strongyloid\*strongyloides NEAR infection\$albendazole4mebendazolestrongyloides infection\*strongyloides infection\*strongyloides NEAR stercoralismebendazole5anthelmint\*1 or 2 or 3 or 41 or 2 or 3 or 41 or 2 or 3 or 4anthelmint\*6ivermectin\*thiabendazolethiabendazoleTHERAPY2 or 3 or 4 or 572 or 3 or 4 or 5 or 6albendazolealbendazoleTREATMENT1 and 681 and 7mebendazolemebendazolethiabendazole---9---anthelmint\$anthelmint\$albendazole---10---ivermectin\*ivermectin\*mebendazole---11---6 or 7 or 8 or 9 or 106 or 7 or 8 or 9 or 10anthelmint\$---12---5 and 115 and 11ivermectin\$---13---------6 or 7 or 8 or 9 or 10 or 11 or 12---14---------5 and 13---

^a^CIDG Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration ([@CD007745-bbs2-0069]); upper case: MeSH or EMTREE heading; lower case: free text term.

Comparison 1Ivermectin versus albendazoleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Parasitological cure](#CD007745-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Ivermectin versus albendazole, Outcome 1 Parasitological cure.4478Risk Ratio (M‐H, Fixed, 95% CI)1.79 \[1.55, 2.08\][2 Parasitological cure (type of population)](#CD007745-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Ivermectin versus albendazole, Outcome 2 Parasitological cure (type of population).4Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only2.1 Endemic3425Risk Ratio (M‐H, Fixed, 95% CI)1.75 \[1.50, 2.04\]2.2 Non‐endemic153Risk Ratio (M‐H, Fixed, 95% CI)2.21 \[1.28, 3.80\][3 Parasitological cure (doses of ivermectin)](#CD007745-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Ivermectin versus albendazole, Outcome 3 Parasitological cure (doses of ivermectin).4Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only3.1 Ivermectin (single dose) versus albendazole4434Risk Ratio (M‐H, Fixed, 95% CI)1.85 \[1.57, 2.16\]3.2 Ivermectin (double doses) versus albendazole144Risk Ratio (M‐H, Fixed, 95% CI)1.40 \[0.96, 2.02\][4 Parasitological cure (sensitivity analysis)](#CD007745-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Ivermectin versus albendazole, Outcome 4 Parasitological cure (sensitivity analysis).2354Risk Ratio (M‐H, Fixed, 95% CI)1.89 \[1.58, 2.27\][5 Clinical adverse events](#CD007745-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Ivermectin versus albendazole, Outcome 5 Clinical adverse events.4518Risk Ratio (M‐H, Fixed, 95% CI)0.80 \[0.59, 1.09\]

Comparison 2Ivermectin versus thiabendazoleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Parasitological cure](#CD007745-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Ivermectin versus thiabendazole, Outcome 1 Parasitological cure.3467Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.96, 1.20\][2 Parasitological cure (type of population)](#CD007745-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Ivermectin versus thiabendazole, Outcome 2 Parasitological cure (type of population).3Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only2.1 Endemic1216Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.94, 1.22\]2.2 Non‐endemic2251Risk Ratio (M‐H, Fixed, 95% CI)1.08 \[0.90, 1.29\][3 Parasitological cure (doses of ivermectin)](#CD007745-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Ivermectin versus thiabendazole, Outcome 3 Parasitological cure (doses of ivermectin).3Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only3.1 Ivermectin (single dose) versus thiabendazole2414Risk Ratio (M‐H, Fixed, 95% CI)1.08 \[0.95, 1.22\]3.2 Ivermectin (double doses) versus thiabendazole153Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.93, 1.21\][4 Clinical adverse events](#CD007745-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Ivermectin versus thiabendazole, Outcome 4 Clinical adverse events.3507Risk Ratio (M‐H, Random, 95% CI)0.31 \[0.20, 0.50\]

Comparison 3Ivermectin (single dose) vs ivermectin (double dose)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Parasitological cure](#CD007745-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Ivermectin (single dose) vs ivermectin (double dose), Outcome 1 Parasitological cure.294Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.94, 1.11\]

The analysis of the two types of benzimidazoles (albendazole & thiabendazole) was initially planned as a subgroup analysis within a broad comparison that did not distinguish between both drugs. Given the high heterogeneity between both drugs, we converted the subgroup analysis into two main comparisons. This change was agreed with the CIDG editors.

We changed the \'Risk of bias\' tool during preparation of the review to reflect the changes suggested in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD007745-bbs2-0064]).

We could not explore publication bias using funnel plots because there was an insufficient number of trials in the comparisons (ivermectin versus albendazole: four trials and ivermectin versus thiabendazole: three trials).

As the risk of bias of the trials was similar we could not conduct sensitivity analyses.

We have added new authors have been added to the review team: Maria N Plana (MNP) and Jose A Perez‐Molina.

Characteristics of included studies \[ordered by study ID\] {#CD007745-sec2-0019}
===========================================================

[@CD007745-bbs2-0001]MethodsRCT.\
Length of follow‐up: 4 weeks post‐treatment.ParticipantsNumber randomized: 252 participants (216 participants completed the trial: 21 treatment withdrawals and 15 losses to follow‐up).\
Inclusion criteria: aged 5 to 66 years old, with uncomplicated intestinal strongyloidiasis and whose stools were positive of *S. stercoralis* larvae during a survey on intestinal helminths.\
Exclusion criteria: they had no received any form of anti‐filarial therapy and any other antihelmintic treatment in the 6 months and 72 hours respectively, preceding the trial. Only subjects with no allergic diathesis, disseminated strongyloidiasis, severe renal, hepatic, haematological (haemoglobin level under 5 g/dL) or cardiovascular functions participated in the trial. Potentially childbearing women not using contraceptives and subjects in which the parasite was detected in stool samples more than 30 days before commencement of the trial were excluded. Patients were recruited through a community survey and signs and symptoms such as epigastric pain, urticaria, and diarrhoea were recorded.InterventionsIvermectin 200 μg/kg single dose (N = 126) versus thiabendazole 50 mg/kg/day for 3 days (N = 126).OutcomesDrug efficacy: negative stool test at 7, 21 and 30 days. A subject was considered parasitologically cured, if all 3 post‐treatment stool samples tested negative for *S. stercoralis.* All patients who did not provide all 3 follow‐up stool samples were excluded from the analysis of drug efficacy.\
Clinical adverse events were investigated through voluntary spontaneous complaints and also by interviews conducted using a standard questionnaire within 7 days post‐treatment.NotesDiagnostic method: Baermann.\
Place: Yewa South, Nigeria‐Africa.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskTreatment regimens were randomized from a list for the sequential allocation of the drugs, prepared in advance.Allocation concealment (selection bias)High riskWe do not know how allocation was concealed. Probably not done.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel but we don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding of participants and personnel and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskNo blinding, but the we judge that the outcome measurement is unlikely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding and the outcome measurement are likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesUnclear risk36/252 participants (14.3%) lost during follow‐up period (13/126: 9 lost to follow‐up and 4 incomplete treatment in the ivermectin arm and 23/126: 9 lost to follow‐up and 17 incomplete treatment in the thiabendazole arm). No reasons for missing data provided. Per‐protocol analysis.Selective reporting (reporting bias)Low riskThe trial protocol is not available but it is clear that the published report include all expected outcomes.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD007745-bbs2-0002]MethodsRCT.\
Length of follow‐up: 16 to 24 weeks post‐treatment.ParticipantsNumber randomized: 223\
Inclusion criteria: aged 5 to 85 years old. Eligible patients were male and female subjects older than 5 years and weighing \> 15 kg. They were travellers, immigrants residents, and autochthonous residents living in Italy. They had no have a diagnosis of strongyloidiasis established by IFAT.\
Exclusion criteria: pregnancy or breastfeeding; CNS diseases; disseminated strongyloidiasis: immunodeficiency (malignancies, chemotherapy or other immunosuppressive treatments); planned travel to endemic countries before follow‐up; lack of informed consent. HIV positive subjects were excluded if CD4 count was lower than 400/µL. Baseline signs and symptoms (not reported) were recorded.InterventionsIvermectin 200 μg/kg single dose (N = 115) versus thiabendazole two daily doses of 25 mg/kg/day for 2 days (N = 108).OutcomesDrug efficacy: cure at Time 2 (Time 2: 4 to 6 months after recruitment), defined as follows: negative stool agar culture and negative IFAT or decrease of two or more antibody titres.\
Adverse events reported by the patients.NotesDiagnostic method: stool agar culture and IFAT.\
Place: Italian travellers attended at Sacro‐Cuore Hospital, Verona‐Italy.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization list was computer‐generated by a biostatistician who was not directly involved in the trial and handled to a nurse who was not involved in the trial. The patients received an unique ID number.Allocation concealment (selection bias)Low riskThe list was kept in a locked drawer. As randomization was not in blocks, there was no way for the investigator to guess in advance the next assignment treatment.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel, but we don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding, and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskBlinding of laboratory staff was ensured: the laboratory personnel performing the analyses (stool culture, serology) had no direct contact with the investigators and no information as regards the drug administered to the patients.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding, and the outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesUnclear risk25/223 participants (11.2%) lost during follow‐up. Compliance to follow‐up was higher for ivermectin (106/115 or 92.2%) than thiabendazole (92/108 or 85.2%). No reasons for missing data provided. Per‐protocol analysis.Selective reporting (reporting bias)Low riskThe trial protocol is available and all of the trial\'s pre‐stated outcomes that are of interest in the review have been reported.Other biasUnclear riskRecruitment was concluded before the required sample size was obtained. The reason was the important difference in tolerability observed between the two arms. This was not an explicitly defined criteria for the early conclusion of the trial (all observed adverse events were mild to moderate).[@CD007745-bbs2-0003]MethodsRCT.\
Lenght of follow‐up: 12 weeks.ParticipantsNumber randomized: 60 participants\
Inclusion criteria: adults and children (5 to 70 years). Patients were admitted to the trial if *S. stercoralis* had been detected in a stool sediment within 30 days preceding the trial.\
Exclusion criteria: they did not show any indication of disseminated strongyloidiasis, acute or serious illness, or any marked abnormality of liver, renal, hematopoietic or cardiovascular function, and had not received any other antifilarial drug in the 6 months, or other antihelmintic treatment in the 72 hours preceding the trial. Potentially child‐bearing women who were not using contraceptives were excluded, also. Baseline signs and symptoms such as pruritus was recorded (the trial refers that clinical outcome was favourable in all the patients who were cured, except for one who complained of persistent pruritus, which was not related to strongyloidiasis).InterventionsIvermectin 150 to 200 μg/kg in a single dose (N = 32) and albendazole 400 mg/day for 3 days (N = 28).OutcomesDrug efficacy: negative stool samples (7, 30, and 90 days). Tolerance was evaluated at each visit by a thorough questionnaire and physical examination. Hepatic, renal and haematological functions were investigated before treatment and on day 7.NotesDiagnostic method: smear examination, Kato thick smears, formalin‐ether concentrations, and Baermann.\
Place: residents in France coming from sub‐Saharan Africa, Caribbean, south‐east Asia, and Latin America.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"Patients were randomly assigned to either ivermectin or albendazole treatment\". We do not know how the randomization was done.Allocation concealment (selection bias)High riskWe do not know how allocation was concealed. Probably not done.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel but review authors don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding, and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskThis was an open‐label trial. Therefore blinding of laboratory staff was ensured (the laboratory personnel performing the analyses (stool culture, serology) had no direct contact with the investigators and no information as regards the drug administered to the patient.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding, and the outcome is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesUnclear risk7/60 patients were not included in the analysis (4 belonged to the albendazole group and 3 to the ivermectin group). The reasons for missing data were inadequate follow‐up (4 patients) and inclusion faults (diagnosis of *S. stercoralis* infection more than 30 days before enrolment (two) and concomitant anthelmintic therapy (one). Per‐protocol analysis.Selective reporting (reporting bias)Low riskNo protocol provided, but given the outcomes nominated in the methods section, all pre‐specified outcomes were reported.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD007745-bbs2-0004]MethodsRCT.\
Lenght of follow‐up: 12 weeks.ParticipantsNumber randomized: 53 participants.\
Inclusion criteria: aged 5 to 70 years old. People suspected of having strongyloidiasis were identified through neighbourhood clinics, schools, primary care physicians and hospital laboratories in Lowell. Patients were suspected of being infected on the basis of symptoms, eosinophilia, or positive serology. Baseline signs and symptoms such as epigastric pain, diarrhoea, losing weight, urticaria and cough were recorded.\
Inclusion criteria: Non‐pregnant 5‐ to 70‐year‐old patients with stool tests positive for *S. stercoralis*.\
Exclusion criteria: people with no signs of hyperinfection or major concurrent illness.InterventionsIvermectin 200 μg/kg single dose (N = 16). Ivermectin 200 μg/kg for 2 consecutive days (N = 18) or thiabendazole 25 mg/kg twice per day for 3 days (N = 19).OutcomesDrug efficacy: negative stool samples (7, 30, 90, and 180 days). Subsequent stool examinations done 10 and 22 months after treatment. To assess adverse reactions and encourage total compliance, patients were contacted daily during treatment by a Cambodian‐speaking research assistant. To assess drug safety, we took patient histories, did physical examinations, and ran complete blood cell counts and serum chemistries (including liver function tests) shortly before and on day 7 after treatment.NotesDiagnostic method: Baermann.\
Place: Southeast Asian refugees living in Lowell, USA.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskPatients were randomly assigned (using Social Security number and a random number table).Allocation concealment (selection bias)High riskNo information was supplied regarding concealment. Probably not done.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel but we don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding, and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskLaboratory personnel conducting stool and blood testing were blinded to the patients treatment group.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding, and the outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesLow risk1/16 (6%), 0/18 (0%), and 0/19 (0%) lost during 3 months of follow‐up period. Per‐protocol analysis.Selective reporting (reporting bias)Low riskNo protocol provided, but given the outcomes nominated in the methods section, all pre‐specified outcomes were reported.Other biasLow riskNo additional biases were identified.[@CD007745-bbs2-0005]MethodsRCT.\
Lenght of follow‐up: 3 weeks.ParticipantsNumber randomized: 417 participants.\
Inclusion criteria: schoolchildren aged 9 to 22 years old. Inclusion criteria: any individual with demonstrated first or third‐stage larvae of *S. stercoralis* on stool sample was included in the trial.\
Exclusion criteria: consent not given; fever or other signs of acute illness; severe neurologic disorders; severe liver disorders; and pregnancy. Baseline signs and symptoms such as cough, abdominal distention, diffuse itching, urticaria, and larva migrans were recorded.InterventionsIvermectin 200 /kg single dose (N = 208) versus albendazole 400 mg/day for 3 days (N = 209).OutcomesDrug efficacy: negative stool samples (3 and 21 days). Symptoms of strongyloidiasis and adverse effects of the two drugs according to the literature were detailed beforehand. The list was translated from English into Kiswahili and back to English to ensure correct interpretation of the findings. The interviews were carried out in Kiswahili by a medical assistant of the Ministry of Health. Special symptoms were recorded on a separate sheet, where the findings of a thorough clinical examination were also recorded.NotesKato‐Katz smear and Baermann.\
Place: Zanzibar.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskA randomized list for the sequential allocation of the drugs was prepared in advance.Allocation concealment (selection bias)High riskWe do not know how allocation was concealed. Probably not done.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel but we don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding, and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskNo blinding, but we judge that the outcome measurement is unlikely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding, and the outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesHigh risk116/ 417 (28%) lost during follow‐up period (56/208 (27%):45 incomplete questionnaire or treatment and 11 incomplete follow‐up in the ivermectin arm and 60/209 (29%): 39 incomplete questionnaire or treatment and 21 incomplete follow‐up in the albendazole arm). Per‐protocol analysis.Selective reporting (reporting bias)Low riskNo protocol provided, but given the outcomes nominated in the methods section, all pre‐specified outcomes were reported.Other biasLow riskNo additional biases were identified.[@CD007745-bbs2-0006]MethodsRCT.\
Leght of follow‐up: 2 to 3 weeks.ParticipantsNumber randomized: 42 participants.\
Inclusion criteria: Adult people (included immunocompromised patients: 5 immunosuppressive drugs users, 3 AIDS/HIV patients, 2 hematological malignancy patients). Aged 22 to 87 years old, were recruited if characteristic rhabditiform larvae of *S. stercoralis* were present on faecal microscopy. Baseline signs and symptoms such as abdominal pain, diarrhoea and nausea/vomiting were recorded.\
Exclusion criteria: a history of allergic reaction to either trial medication, treatment in the month prior to the trial with any drug known to have anti‐Strongyloides activity, pregnancy or lactation, and any suggestion of disseminated strongyloidiasis.InterventionsIvermectin 200 μg/kg single oral dose (parenteral veterinary preparation) (N = 21) and albendazole 800 mg daily for 7 days (N = 21).OutcomesDrug efficacy: negative stool samples 7 days. Adverse events were reported.NotesDiagnostic method: smear examination and formol‐ether concentration.\
Place: Thailand, Siriraj Hospital.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskPatients were randomly allocated. We do not know how the randomization was done.Allocation concealment (selection bias)High riskWe do not know how allocation was concealed. Probably not done.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel but we don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding of participants and personnel and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskNo blinding, but we judge that the outcome measurement is unlikely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding, and the outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesLow riskFive patients were lost from the albendazole group and three from the ivermectin group, during median follow‐up periods of 13 days (range 6 to 85 days) and 19 days (3 to 117 days), respectively. Per‐protocol analysis.Selective reporting (reporting bias)Low riskNo protocol provided, but given the outcomes nominated in the methods section, all pre‐specified outcomes were reported.Other biasLow riskNo additional biases were identified.[@CD007745-bbs2-0007]MethodsRCT.\
Leght of follow‐up: seven hospital visits (baseline, 2 weeks, 1, 3, 6 and 9 months, and 1 year after treatment.ParticipantsNumber randomized: 100 participants.\
Inclusion criteria: aged 23 to 81 years (included immunocompromised patients: 10 AIDS/HIV patients, 32 immunosuppressive drugs user patients, 9 hematological malignancy patients) recruited if characteristic rhabditiform larvae of *S. stercoralis* were present on fecal microscopy. Baseline signs and symptoms such as abdominal pain, diarrhoea, and nausea/vomiting were recorded.\
Exclusion criteria: history of allergic reaction to either trial medication, treatment within the month prior to the trial with any drug known to have anti‐strongyloides activity, pregnancy or lactation and any suggestion of disseminated strongyloidiasis.InterventionsThree arms: ivermectin 200 μg/kg single oral dose (N = 32), ivermectin two oral doses of 200 μg/kg given 2 weeks apart (N = 32), and albendazole 800 mg daily for 7 days (N = 36).OutcomesDrug efficacy: cure was defined as clinical improvement and the absence of rhabditiform larvae in the stool at day 14 of treatment and through the follow‐up period. Adverse events and laboratory abnormalities were reported.NotesDiagnostic method: direct smear, formol‐ether concentration method and modified Koga agar plate culture.\
Place: Thailand, Siriraj Hospital.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated, simple, random allocation sequences were prepared for 3 trial groups by the investigator team.Allocation concealment (selection bias)Low riskThese were sealed in an opaque envelope and numbered. The investigator (YS) assigned trial participants to their respective treatment group after opening the sealed envelope.Blinding of participants and personnel (performance bias) Cure overallLow riskNo blinding of participants and personnel but we don\'t believe this will introduce bias.Blinding of participants and personnel (performance bias) Adverse events overallHigh riskNo blinding of participants and personnel and the outcome is likely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Cure overallLow riskNo blinding, but we judge that the outcome measurement is unlikely to be influenced by lack of blinding.Blinding of outcome assessment (detection bias) Adverse events overallHigh riskNo blinding, and the outcome measurement is likely to be influenced by lack of blinding.Incomplete outcome data (attrition bias) All outcomesUnclear riskSix patients were excluded in the albendazole group (3 deaths before treatment and 3 lost to follow‐up), one patient was lost to follow‐up in one arm of the ivermectin, an one patient was lost to follow‐up in the other arm of ivermectin. Per‐protocol analysis.Selective reporting (reporting bias)Low riskNo protocol provided, but given the outcomes nominated in the methods section, all pre‐specified outcomes were reported.Other biasLow riskNo additional biases were identified.

Characteristics of excluded studies \[ordered by study ID\] {#CD007745-sec2-0020}
===========================================================

StudyReason for exclusion[@CD007745-bbs2-0008]Participants not randomized, no control group.[@CD007745-bbs2-0009]Participants not randomized.[@CD007745-bbs2-0010]Participants not randomized, no control group.[@CD007745-bbs2-0011]Ivermectin is not a control group.[@CD007745-bbs2-0012]Participants not randomized, no control group.[@CD007745-bbs2-0013]Participants not randomized, no control group.[@CD007745-bbs2-0014]Participants not randomized, no control group.[@CD007745-bbs2-0015]Participants not randomized, no control group.[@CD007745-bbs2-0016]Participants not randomized, no control group.[@CD007745-bbs2-0017]Participants not randomized.[@CD007745-bbs2-0018]Participants not randomized.[@CD007745-bbs2-0019]Participants not randomized, no control group.[@CD007745-bbs2-0020]Participants not randomized, no control group.[@CD007745-bbs2-0021]Trial with different intervention. Ivermectin is not a control group.[@CD007745-bbs2-0022]No control group.[@CD007745-bbs2-0023]Participants not randomized, no control group.[@CD007745-bbs2-0024]Probably a non‐randomized design.[@CD007745-bbs2-0025]Participants not randomized, no control group.[@CD007745-bbs2-0026]Ivermectin is not a control group.[@CD007745-bbs2-0027]Trial used participants who tested negative for *S. stercoralis* at baseline.[@CD007745-bbs2-0028]Participants not randomized.[@CD007745-bbs2-0029]Did not meet our inclusion criteria: different interventions of interest.[@CD007745-bbs2-0030]Did not meet our inclusion criteria: different interventions of interest.[@CD007745-bbs2-0031]Probably a non‐randomized design.[@CD007745-bbs2-0032]No control group.[@CD007745-bbs2-0033]Participants not randomized.[@CD007745-bbs2-0034]Participants not randomized.[@CD007745-bbs2-0035]Participants not randomized.[@CD007745-bbs2-0036]Participants not randomized.[@CD007745-bbs2-0037]Ivermectin is not a control group.[@CD007745-bbs2-0038]Did not fit with our inclusion criteria: different interventions of interest.[@CD007745-bbs2-0039]Participants not randomized.[@CD007745-bbs2-0040]Cross‐sectional trial.[@CD007745-bbs2-0041]Not a RCT.[@CD007745-bbs2-0042]Ivermectin is not a control group. Cohort trial.[@CD007745-bbs2-0043]Participants not randomized.

Characteristics of ongoing studies \[ordered by study ID\] {#CD007745-sec2-0021}
==========================================================

[@CD007745-bbs2-0044]Trial name or titleMultiple versus single dose of ivermectin for the treatment of strongyloidiasis (STRONGTREAT)\
Trial registration number (EudraCT number): 2011‐002784‐24MethodsRandomized, open‐label, multi centre Phase III clinical trial on multiple versus single dose of ivermectin for the treatment of strongyloidiasisParticipantsInclusion criteria: male and female patients older than 5 years and weighting \> 15 kg. Current residence in non‐endemic areas. Either direct diagnosis of *S. stercoralis* infection and positive serology at any titre or positive serology at \"high\" titre, irrespective of results of direct tests.\
Exclusion criteria: pregnant or lactating women; subjects suffering from CNS diseases; disseminated strongyloidiasis; immunocompromised patients; lack of informed consent; previous treatment with ivermectin (in the last year).InterventionsExperimental: ivermectin multiple doses (a dose of 200 μg/kg of ivermectin given on days 1,2, 15 and 16).\
Active comparator: 1 dose ivermectin (a single 200 μg/kg dose of ivermectin).OutcomesPrimary outcome: clearance of strongyloides infection (clearance of infection is defined by negative stool agar/charcoal culture ‐ direct examination of three faecal samples for *S. stercoralis* and negative serology or decrease in titre below a defined cutoff.\
Secondary outcome: all‐cause mortality during the 12 months of follow‐up. Patients with partial response to treatment at T2. Patients with adverse reactions. Time Frame: from 1st to 5th day of treatment and from 15th to 19th day (or 72 hours from treatment completion). Patients with increase in blood ALT over cutoff value. Patients with decrease in WBC count below cutoff value. Average difference in blood ALT and WBC count at day 17, compared with baseline. Average difference in blood eosinophil count at T2, compared with baseline.Starting dateMarch 2013Contact informationDora Buonfrate, MD ([dora.buonfrate\@sacrocuore.it](dora.buonfrate@sacrocuore.it)) +39 601 3563NotesFunders: European Comission‐Framework VII
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[^2]: ^1^Downgraded by 1 for risk of bias: two trials did not conceal allocation, and no method of allocation is described. ^2^Downgraded by 1 for imprecision: wide range of estimates on 3 trials could include substantive fewer events to a few more.

[^3]: ^1^Downgraded by 1 for risk of bias: 2 trials did not conceal allocation, and no method of allocation is described in one trial.

[^4]: Abbreviations: AEs: adverse events.
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